Skip to content
About Us
About BriaCell
Board of Directors
Management Team
Scientific Advisory Board
Corporate Governance
Privacy Policy
Technology
BriaIMT
BriaOTS
MOA
PKC
δ
Patents
Clinical Trials
Scientific Publications
Patients
What is BriaCell therapy?
How can cancer patients get BriaCell therapy?
Clinical Trial
Expanded Access
Recent Media
Investor Relations
Presentation & Fact Sheet
News and Events
Filings & Shareholder Info
Analyst Coverage
Email Alerts
Contact Us
Monthly Archives:
October 2018
BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®
October 9, 2018
· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck ...
About Us
About BriaCell
Board of Directors
Management Team
Scientific Advisory Board
Corporate Governance
Privacy Policy
Technology
BriaIMT
BriaOTS
MOA
PKC
δ
Patents
Clinical Trials
Scientific Publications
Patients
What is BriaCell therapy?
How can cancer patients get BriaCell therapy?
Clinical Trial
Expanded Access
Recent Media
Investor Relations
Presentation & Fact Sheet
News and Events
Filings & Shareholder Info
Analyst Coverage
Email Alerts
Contact Us
Home
Sign Up for Email Alert
Careers
TSX-V:BCT:
(%)
NASDAQ:BCTX:
(%)